Boosting CAR-T Therapy with the Ketogenic Diet
A study from the University of Pennsylvania suggests that a ketogenic diet enhances the effectiveness of CAR T cell therapy in treating lymphoma by utilizing beta-hydroxybutyrate (BHB) as a preferred energy source over glucose. This approach led to improved tumor control and survival in mice, with translational studies indicating similar benefits in human samples. A Phase I clinical trial is underway to test BHB supplementation in lymphoma patients, potentially offering a low-toxicity, cost-effective strategy to boost cancer immunotherapy outcomes.
